S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(-0.80%) $83.18
Gas
(1.09%) $1.944
Gold
(-0.32%) $2 339.70
Silver
(0.00%) $27.54
Platinum
(0.61%) $927.70
USD/EUR
(-0.27%) $0.932
USD/NOK
(-0.28%) $10.99
USD/GBP
(-0.32%) $0.798
USD/RUB
(0.25%) $92.11

Realaus laiko atnaujinimai Abbott Laboratories [ABL.DE]

Birža: XETRA Pramonė: Health Care Equipment & Services
Atnaujinta26 bal. 2024 @ 18:35

1.06% 100.52

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...

Stats
Šios dienos apimtis 823.00
Vidutinė apimtis 592.00
Rinkos kapitalizacija 174.42B
EPS €0 ( 2024-04-17 )
Kita pelno data ( €0 ) 2024-07-17
Last Dividend €0.510 ( 2023-07-13 )
Next Dividend €0 ( N/A )
P/E 33.51
ATR14 €0 (0.00%)

Abbott Laboratories Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Abbott Laboratories Finansinės ataskaitos

Annual 2023
Pajamos: €40.11B
Bruto pelnas: €22.13B (55.18 %)
EPS: €3.28
FY 2023
Pajamos: €40.11B
Bruto pelnas: €22.13B (55.18 %)
EPS: €3.28
FY 2022
Pajamos: €43.65B
Bruto pelnas: €24.51B (56.15 %)
EPS: €3.99
FY 2021
Pajamos: €43.08B
Bruto pelnas: €24.54B (56.97 %)
EPS: €4.00

Financial Reports:

No articles found.

Abbott Laboratories Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.470
(N/A)
€0.470
(N/A)
€0.510
(N/A)
€0.510
(N/A)
€0.510
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Abbott Laboratories Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 4.40 - low (46.12%) | Divividend Growth Potential Score: 7.33 - Increase likely (46.66%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.325 2008-01-11
Last Dividend €0.510 2023-07-13
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 64 --
Total Paid Out €22.13 --
Avg. Dividend % Per Year 0.00% --
Score 3.9 --
Div. Sustainability Score 4.40
Div.Growth Potential Score 7.33
Div. Directional Score 5.87 --
Next Divdend (Est)
(2024-07-01)
€0 Estimate 22.50 %
Dividend Stability
0.60 Above Average
Dividend Score
3.90
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
RWE.DE Ex Dividend Junior 2023-05-05 Annually 0 0.00%
CAR.DE Ex Dividend Knight 2023-06-06 Annually 0 0.00%
KEL.DE Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%
TIMA.DE Ex Dividend Junior 2023-05-10 Annually 0 0.00%
DMP.DE Ex Dividend Knight 2023-06-15 Annually 0 0.00%
MTE.DE Ex Dividend Junior 2023-07-07 Quarterly 0 0.00%
68V.DE Ex Dividend Knight 2023-08-07 Quarterly 0 0.00%
WAF.DE Ex Dividend Junior 2023-05-08 Annually 0 0.00%
FIE.DE Ex Dividend Junior 2023-07-14 Annually 0 0.00%
PAH3.DE Ex Dividend Knight 2023-07-03 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1401.5007.2110.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.1481.5009.4710.00[0.1 - 1]
payoutRatioTTM0.474-1.0005.26-5.26[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM22.041.0002.952.95[3 - 30]
operatingCashFlowPerShareTTM3.502.008.8310.00[0 - 30]
freeCashFlowPerShareTTM2.452.008.7710.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.5521.0004.134.13[0.2 - 0.8]
operatingProfitMarginTTM0.1581.0008.848.84[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.40

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM33.431.0006.720[1 - 100]
returnOnEquityTTM0.1482.509.6610.00[0.1 - 1.5]
freeCashFlowPerShareTTM2.452.009.1810.00[0 - 30]
dividendYielPercentageTTM1.9711.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM3.502.008.8310.00[0 - 30]
payoutRatioTTM0.4741.5005.26-5.26[0 - 1]
pegRatioTTM6.471.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1521.0008.710[0.1 - 0.5]
Total Score7.33

Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.